Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen is participating in an overseas IR conference in Hong Kong and Singapore from February 17 to February 20, 2025, to present its R&D pipelines, progress on licensed agreements, and long-term growth strategies to foreign institutional investors.
📊 [Key Disclosure Details & Financial Highlights]
- Date & Time: 2025-02-17 ~ 2025-02-20 (09:00 ~ 18:00 Local Time)
- Location: Hong Kong, Singapore
- Target Audience: Foreign institutional investors, etc.
- Purpose: Introduction of main R&D and business status to foreign investors
- Event Format: Participation in ‘KIS Korea Investors Conference 2025’ hosted by Korea Investment & Securities
- Key Agenda: Progress updates on licensed technology items, introduction of long-term growth strategies
- Host/Sponsor: Korea Investment & Securities
- Scheduled IR Material Upload Date & Location: 2025-02-17 / Korea Exchange KIND system (http://kind.krx.co.kr)
- Department in Charge: IR Group (+82-42-384-8777)
- Confirmation Date: 2025-02-14
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 IR Presentation Filing and Review of Licensed Pipeline Updates
This overseas IR event provides a platform to share updates on existing licensing agreements and long-term strategy directly with Asian financial hub institutional investors. Checking the IR presentation materials disclosed on the first day of the conference is important to evaluate the exact development timelines and strategic direction of major licensed pipelines. The official presentation materials can be accessed on or after February 17, 2025, via the ‘IR Material Filing’ section on the Korea Exchange KIND system or the IR section of Alteogen’s official website.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
